Skip to main content
Home
OUR XCHANGES
BY TOPIC
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
MEDTECH STRATEGY
OLIGONUCLEOTIDES & PEPTIDES
BY LOCATION
BOSTON, USA
SAN FRANCISCO, USA
MUNICH, EU
PAST EVENTS
INDUSTRY EXPERTS
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY DRUG CONJUGATES THERAPEUTICS
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
MEDTECH STRATEGY
OLIGONUCLEOTIDES & PEPTIDES
NEWS XCHANGE
PARTNERSHIPS
OUR PARTNERS
BECOME A PARTNER
MEDIA PARTNERS
ABOUT US
GET TO KNOW US
FAQS
MEET THE TEAM
GALLERY
CONTACT US
Home
OUR XCHANGES
BY TOPIC
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
MEDTECH STRATEGY
OLIGONUCLEOTIDES & PEPTIDES
BY LOCATION
BOSTON, USA
SAN FRANCISCO, USA
MUNICH, EU
PAST EVENTS
INDUSTRY EXPERTS
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY DRUG CONJUGATES THERAPEUTICS
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
MEDTECH STRATEGY
OLIGONUCLEOTIDES & PEPTIDES
NEWS XCHANGE
PARTNERSHIPS
OUR PARTNERS
BECOME A PARTNER
MEDIA PARTNERS
ABOUT US
GET TO KNOW US
FAQS
MEET THE TEAM
GALLERY
CONTACT US
Sponsorship Enquiry
Register For Free
Home
OUR XCHANGES
BY TOPIC
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
MEDTECH STRATEGY
OLIGONUCLEOTIDES & PEPTIDES
BY LOCATION
BOSTON, USA
SAN FRANCISCO, USA
MUNICH, EU
PAST EVENTS
INDUSTRY EXPERTS
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY DRUG CONJUGATES THERAPEUTICS
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
MEDTECH STRATEGY
OLIGONUCLEOTIDES & PEPTIDES
NEWS XCHANGE
PARTNERSHIPS
OUR PARTNERS
BECOME A PARTNER
MEDIA PARTNERS
ABOUT US
GET TO KNOW US
FAQS
MEET THE TEAM
GALLERY
CONTACT US
Industry Experts
Loading
Alejandro Rendon
Senior Director of Product Development,
Shifamed
Sessions
23-Sep-2025
09:05 – 10:05
Roundtable: How can companies ensure that the engineering design is adaptable to mass production without incurring high rework costs?
LinkedIn
YouTube
Search
Search
Search
Username *
Password *
Login